Moderna, Inc. (NASDAQ:MRNA) Given Average Rating of “Hold” by Brokerages

Moderna, Inc. (NASDAQ:MRNA) has been given an average rating of “Hold” by the sixteen ratings firms that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and six have given a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $126.49.

A number of research firms have recently commented on MRNA. Jefferies Financial Group restated a “buy” rating and set a $125.00 price objective on shares of Moderna in a research note on Tuesday, April 9th. Canaccord Genuity Group increased their price objective on shares of Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a research note on Friday, February 23rd. HSBC restated a “reduce” rating and set a $86.00 price objective (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Thursday, April 11th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $125.00 price objective on shares of Moderna in a research note on Thursday, March 28th.

Moderna Price Performance

MRNA opened at $111.46 on Thursday. The company has a quick ratio of 3.36, a current ratio of 3.42 and a debt-to-equity ratio of 0.04. Moderna has a 12 month low of $62.55 and a 12 month high of $142.79. The company has a fifty day simple moving average of $103.95 and a 200 day simple moving average of $93.92. The stock has a market cap of $42.68 billion, a P/E ratio of -8.98 and a beta of 1.62.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. The firm had revenue of $2.80 billion during the quarter, compared to analysts’ expectations of $2.53 billion. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The company’s revenue was down 44.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.61 EPS. On average, research analysts expect that Moderna will post -7.51 EPS for the current year.

Insiders Place Their Bets

In other Moderna news, insider Shannon Thyme Klinger sold 544 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $99.05, for a total transaction of $53,883.20. Following the completion of the sale, the insider now directly owns 9,267 shares in the company, valued at $917,896.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, President Stephen Hoge sold 2,388 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $225,833.16. Following the transaction, the president now directly owns 1,515,898 shares of the company’s stock, valued at $143,358,473.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Shannon Thyme Klinger sold 544 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $99.05, for a total transaction of $53,883.20. Following the transaction, the insider now directly owns 9,267 shares in the company, valued at $917,896.35. The disclosure for this sale can be found here. Insiders sold 124,954 shares of company stock worth $13,158,776 over the last three months. Insiders own 15.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Allworth Financial LP increased its holdings in shares of Moderna by 6.5% during the fourth quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock worth $165,000 after purchasing an additional 101 shares during the period. TIAA Trust National Association increased its stake in Moderna by 2.3% in the fourth quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock valued at $447,000 after acquiring an additional 102 shares during the last quarter. Principle Wealth Partners LLC increased its stake in Moderna by 4.3% in the first quarter. Principle Wealth Partners LLC now owns 2,497 shares of the company’s stock valued at $266,000 after acquiring an additional 102 shares during the last quarter. Sound Income Strategies LLC increased its stake in Moderna by 17.8% in the fourth quarter. Sound Income Strategies LLC now owns 762 shares of the company’s stock valued at $76,000 after acquiring an additional 115 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in Moderna by 32.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock valued at $47,000 after acquiring an additional 116 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.